CSPC Pharmaceutical Group (HKG:1093) obtained clinical trial approval for JMT202 from the US Food and Drug Administration, a Friday Hong Kong bourse filing said.
The drug, which is currently undergoing trials in China, can potentially be used to treat metabolism-related diseases such as dyslipidemia, metabolic dysfunction-associated steatohepatitis, type 2 diabetes, and obesity.
The indication for this approval to conduct clinical trials in the US is hypertriglyceridemia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.